ଟାସିମେଲଟେଓନ

ଟାସିମେଲଟେଓନ
Clinical data
Trade names	Hetlioz, Hetlioz LQ
AHFS/Drugs.com	monograph
MedlinePlus	a615004
data	EU EMA: yes; US DailyMed: Tasimelteon;
Pregnancy; category	US: C (Risk not ruled out) ;
Dependence; liability	None
Addiction; liability	None
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	not determined in humans
Protein binding	89–90%
Metabolism	extensive liver, primarily CYP1A2 and CYP3A4-mediated
Elimination half-life	0.9–1.7 h / 0.8–5.9 h (terminal)
Excretion	80% in urine, 4% in feces
Identifiers
	IUPAC name (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide;
ECHA InfoCard	100.114.889
Chemical and physical data
Formula	C15H19NO2
Molar mass	୨୪୫.୩୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2;
	InChI InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 ; Key:PTOIAAWZLUQTIO-GXFFZTMASA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Tasimelteon

ଟାସିମେଲଟେଓନ (ଇଂରାଜୀ ଭାଷାରେ Tasimelteon), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ହେଟଲିଓଜ୍ ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହାକି ଅଣ-24 ଘଣ୍ଟିଆ ନିଦ୍ରା-ଜାଗ୍ରତ ବେମାରୀର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଶୋଇବାର ଏକ ଘଣ୍ଟା ପୂର୍ବରୁ ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧] ^[୩] ଏହି ଚିକିତ୍ସାର ଉପକାର ପାଇବାକୁ ମାସେ ସମୟ ଲାଗିପାରେ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ନିଦ୍ରାଳୁ, ଅଇ, ଏବଂ ମୁଣ୍ଡ ବୁଲାଇବା ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୧] ଏହା ମେଲାଟୋନିନ୍ ରିସେପ୍ଟରକୁ ସକ୍ରିୟ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩]

୨୦୧୪ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୫ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଟାସିମେଲଟେଓନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହି ଔଷଧ ବାବଦ ମାସକୁ ପ୍ରାୟ ୨୩,୦୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୪] ୟୁରୋପରେ ଅନୁମୋଦିତ ଏବଂ ଜର୍ମାନୀରେ ଉପଲବ୍ଧ ଥିବା ସତ୍ତ୍ୱେ ୨୦୨୧ ସୁଦ୍ଧା ବ୍ରିଟେନରେ ଏହା ବିକ୍ରି ହୋଇନଥିଲା ।^[୫]

ଆଧାର

1 2 3 4 5 6 7 "Tasimelteon Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 November 2020. Retrieved 22 September 2021.
↑ "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013. Archived (PDF) from the original on 2013-11-25. Retrieved 2020-12-03.
1 2 3 4 "Hetlioz EPAR". European Medicines Agency (EMA). Archived from the original on 3 November 2020. Retrieved 2 December 2020.
↑ "Hetlioz Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 August 2021. Retrieved 22 September 2021.
↑ "Tasimelteon". SPS - Specialist Pharmacy Service. Archived from the original on 30 November 2020. Retrieved 22 September 2021.

[AHFS2021-1] 1 2 3 4 5 6 7 "Tasimelteon Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 November 2020. Retrieved 22 September 2021.

[2] "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013. Archived (PDF) from the original on 2013-11-25. Retrieved 2020-12-03.

[EPAR2021-3] 1 2 3 4 "Hetlioz EPAR". European Medicines Agency (EMA). Archived from the original on 3 November 2020. Retrieved 2 December 2020.

[4] "Hetlioz Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 August 2021. Retrieved 22 September 2021.

[5] "Tasimelteon". SPS - Specialist Pharmacy Service. Archived from the original on 30 November 2020. Retrieved 22 September 2021.

[୧]

[୨]

[୩]

[୪]

[୫]